PL2257283T3 - L-cytrulina do leczenia zaburzeń erekcji - Google Patents

L-cytrulina do leczenia zaburzeń erekcji

Info

Publication number
PL2257283T3
PL2257283T3 PL09728678T PL09728678T PL2257283T3 PL 2257283 T3 PL2257283 T3 PL 2257283T3 PL 09728678 T PL09728678 T PL 09728678T PL 09728678 T PL09728678 T PL 09728678T PL 2257283 T3 PL2257283 T3 PL 2257283T3
Authority
PL
Poland
Prior art keywords
citrulline
erectile dysfunction
treating erectile
dysfunction
pycnogenol
Prior art date
Application number
PL09728678T
Other languages
English (en)
Inventor
Ermanno Greco
Original Assignee
Androsystems S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Androsystems S R L filed Critical Androsystems S R L
Publication of PL2257283T3 publication Critical patent/PL2257283T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL09728678T 2008-04-02 2009-03-10 L-cytrulina do leczenia zaburzeń erekcji PL2257283T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000567A ITMI20080567A1 (it) 2008-04-02 2008-04-02 L-citrullina per il trattamento della disfunzione endoteliale e della disfunzione erettile.
PCT/EP2009/052799 WO2009121687A1 (en) 2008-04-02 2009-03-10 L-citrulline for treating endothelial dysfunction and erectile dysfunction
EP09728678A EP2257283B9 (en) 2008-04-02 2009-03-10 L-citrulline for treating erectile dysfunction

Publications (1)

Publication Number Publication Date
PL2257283T3 true PL2257283T3 (pl) 2012-05-31

Family

ID=40296835

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09728678T PL2257283T3 (pl) 2008-04-02 2009-03-10 L-cytrulina do leczenia zaburzeń erekcji

Country Status (8)

Country Link
US (1) US8802162B2 (pl)
EP (1) EP2257283B9 (pl)
AT (1) ATE536179T1 (pl)
DK (1) DK2257283T3 (pl)
ES (1) ES2378656T3 (pl)
IT (1) ITMI20080567A1 (pl)
PL (1) PL2257283T3 (pl)
WO (1) WO2009121687A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120093950A1 (en) * 2010-10-19 2012-04-19 Klrm, Llc Compositions and methods for treating, inhibiting the onset, and slowing the progression of erectile dysfunction including naturally occuring age related erectile dysfunction
JP6151646B2 (ja) * 2012-02-15 2017-06-21 協和発酵バイオ株式会社 血管内皮機能低下の予防または改善剤
US9572848B1 (en) 2014-03-26 2017-02-21 Aemes Research L.L.L.P. Composition of matter for sexual dysfunction
WO2019084540A1 (en) 2017-10-27 2019-05-02 Zeta Biolongevity, Inc. COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PROTEINURY AND ENDOTHELIAL EROSION
WO2022027122A1 (en) * 2020-08-06 2022-02-10 Ramade & Cia Holding Corp. Compositions with cannabinoids of cannabis sativa for treating erectile and sexual dysfunction
US12064409B2 (en) * 2021-06-22 2024-08-20 Vanderbilt University Action of L-citrulline to prevent or treat endothelial dysfunction

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4341000A1 (de) 1993-12-02 1995-06-08 Beiersdorf Ag Verwendung von L-Arginin, L-Ornithin oder L-Citrullin und topischen Zubereitungen mit diesen Stoffen
WO2005107735A2 (en) 2004-04-30 2005-11-17 Pump Formulations, Ltd. Nutritional composition for enhancing lean muscle stimulus, growth, strength and recovery, creating and prolonging intense muscle pumps, supporting endurance, strength, performance, size and stamina, providing a transducer effect for nitric oxide, incresing nutrient delivery and/or promoting increased vascular response in a
WO2006002096A2 (en) 2004-06-18 2006-01-05 Vivo Therapeutics, Inc. Low doses of l-citrulline for treating diseases
JP2008536862A (ja) 2005-04-13 2008-09-11 ザ ジェネラル ホスピタル コーポレーション 血管の機能不全のための高用量の葉酸含有組成物
CA2778823A1 (en) * 2006-04-04 2007-10-11 Nestec S.A. Treatments using citrulline

Also Published As

Publication number Publication date
ES2378656T3 (es) 2012-04-16
ITMI20080567A1 (it) 2009-10-03
EP2257283B9 (en) 2012-04-04
US20110044965A1 (en) 2011-02-24
EP2257283B1 (en) 2011-12-07
DK2257283T3 (da) 2012-03-26
US8802162B2 (en) 2014-08-12
EP2257283A1 (en) 2010-12-08
ATE536179T1 (de) 2011-12-15
WO2009121687A1 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
WO2008079460A3 (en) Tyrosine kinase inhibitors for prevention or treatment of infection
CL2007002640A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007002642A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
PL2257283T3 (pl) L-cytrulina do leczenia zaburzeń erekcji
IL199151A (en) Pyrimidine derivatives, their pharmaceutical preparations, their use in cancer treatment and their kits
CL2007002062A1 (es) Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer.
WO2007129226A3 (en) Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
UA100852C2 (ru) Композиции для лечения рака
WO2010132440A3 (en) Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
WO2008155659A3 (en) Compositions for preventing or treating skin defects and methods of use thereof
EP2447274A3 (en) Oligomeric compounds and methods
BR112013030166A2 (pt) método de diferenciação de células haste pluripotentes em células leito vasculares, células endoteliais ou células dos músculos moles vasculares, banco biológico e uso de células endoteliais ou células dos músculos moles vasculares, composição terapêutica, métodos e usos.
MX2009009948A (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa.
BR112012016749A2 (pt) "d-aminoácido para uso no tratamento de biofilmes"
MEP59208A (en) Activin-actriia antagonists and uses for promoting bone growth
SG170751A1 (en) Extractions and methods comprising elder species
BRPI0814529A2 (pt) Derivados de 2-3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas alfa2c para o uso no tratamento de doenças do sistema nervoso periférico e central.
BR112015023495A8 (pt) bebida compreendendo citrato, kit, e, concentrado de bebida
CL2011001147A1 (es) Compuestos derivados de 1,8-diazaespiro [4.5]decan-2-ona, inhibidores de baca; composicion farmaceutica; y su uso en trastornos neurologicos y psiquiatricos.
WO2009158374A3 (en) Inhibitors of akt activity
WO2010052312A3 (fr) Médicament ou composition dermatologique comprenant un extrait peptidique d'avocat destiné au traitement et à la prévention du prurit
UA92861C2 (ru) Фармацевтическая композиция для лечения депрессии и способ ее получения
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
MX2009007384A (es) Formulaciones que contienen ?-lactama con elevada estabilidad en disolucion acuosa.
NO20082838L (no) 9-klor-15-deoksyprostaglandinderivater, fremgangsmate for fremstilling av disse, og anvendelse som medikamenter